REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 6th, 2019 • Nascent Biotech Inc. • Pharmaceutical preparations • California
This Registration Rights Agreement (the “Agreement”), dated as of August 28, 2019 (the “Execution Date”), is entered into by and between Nascent Biotech Inc., a Nevada corporation (the “Company”), and TRITON FUNDS LP, a Delaware limited liability company (the “Investor”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 9th, 2022 • Nascent Biotech Inc. • Pharmaceutical preparations • Nevada
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 6, 2022 by and among NASCENT BIOTECH, INC., a Nevada corporation (the “Company”), and PLATINUM POINT CAPITAL LLC, a Nevada limited liability company (the “Investor”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 9th, 2022 • Nascent Biotech Inc. • Pharmaceutical preparations • Nevada
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of September 6, 2022, is between NASCENT BIOTECH, INC., a company incorporated under the laws of the State of Nevada, with principal executive offices located at 623 17th Street Suite 4, Vero Beach, Florida 32960 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively the “Buyers”).
EXCHANGE AGREEMENT BY AND AMONGExchange Agreement • January 2nd, 2015 • Nascent Biotech Inc. • Pharmaceutical preparations • Nevada
THIS EXCHANGE AGREEMENT (the "Agreement"), is made and entered into as of July 15, 2014, by and among Jin-En International Group Holding Company, a Nevada corporation ("JIN"), Nascent Biotech, Inc., a Nevada corporation ("NBI"), and the stockholders of NBI set forth on the signature pages to this Agreement (collectively, the "Sellers" and individually, a "Seller"), with respect to the following facts:
Confidential Private Placement Subscription Agreement Regulation D San Diego CA 92127 Nascent Biotech Inc. 1,000,000 Shares of Series A Preferred Convertible $1.00 per Share 7% Cumulative Interest 5,000,000 Warrants Minimum Investment: $50,000 PRIVATE...Private Placement Subscription Agreement • December 31st, 2020 • Nascent Biotech Inc. • Pharmaceutical preparations • Nevada
TO: Nascent Biotech Inc. (the “Company”) - Subject and pursuant to the attached “Terms and Conditions” of this Subscription Agreement, including all schedules and appendices attached hereto, the Subscriber hereby irrevocably subscribes for, and on the Closing Date, will purchase from the Company, the following securities at the following price:
LICENSE AGREEMENTLicense Agreement • March 6th, 2015 • Nascent Biotech Inc. • Pharmaceutical preparations • California
This LICENSE AGREEMENT (“Agreement”) is entered into and made effective as of the 6th day of July, 2009 (“Effective Date”) by and between Nascent Biologics, Inc., a Delaware corporation (“Licensee”), and Hideaki Hagiwara and Hagiwara Institute of Health Integrated Medical Sciences Association Foundation, a 501(c)(3) non-profit corporation (“HIHIMSA Foundation” and, together with Hideaki Hagiwara, “Licensor”). Licensor and Licensee are referred to herein collectively as the “Parties” and each individually as a “Party”.
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • September 6th, 2019 • Nascent Biotech Inc. • Pharmaceutical preparations • California
This Common Stock Purchase Agreement (the “Agreement”), dated as of August 28, 2019 (the “Execution Date”), is entered into by and between Nascent Biotech Inc., a Nevada corporation (the “Company”), and TRITON FUNDS LP, a Delaware limited partnership (the “Investor”). The Company and the Investor are individually referred to as a “Party” and collectively as the “Parties”.
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • May 14th, 2020 • Nascent Biotech Inc. • Pharmaceutical preparations • Nevada
This Agreement is entered into as of April 30, 2020 (the “Effective Date”) between Nascent Biotech Inc., a Nevada corporation (“NBIO”) with its principal office located at 6330 Nancy Ridge Dr Suite 105, San Diego, CA 92121, and Manhattan BioSolutions, Inc. a Delaware corporation (“MBS”) with its principal office located at 477 Madison Avenue, 6th Floor, New York, NY 10022, each hereinafter referred to individually as a “Party” and collectively as the “Parties.” The purpose of this Agreement is to set forth the terms and conditions pursuant to research collaboration between NBIO and MBS.
